Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug

Shares of Context Therapeutics CNTX.O rise 9% to $2.89 premarket

Drug developer says U.S. FDA granted fast-track designation to its experimental drug, CTIM-76, for a hard-to-treat ovarian cancer that no longer responds to chemotherapy

CTIM-76 targets platinum-resistant ovarian cancer, meaning the disease has stopped responding to standard platinum-based treatments, co says

Says drug is being tested in an early-stage study in ovarian, endometrial and testicular cancers

CTIM-76 is a bispecific antibody designed to help the immune system find and kill cancer cells, co says

Adds interim results from the study are expected in June 2026

Fast-track status is meant to speed development and review of treatments for serious diseases with unmet medical need

As of last close, stock up ~80% YTD